Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
PE spans from incidental subsegmental disease to obstructive shock. Evaluate pretest probability (e.g., Wells/Geneva), apply age‑adjusted D‑dimer when appropriate, and use CTPA or V/Q based on renal function, pregnancy, and contrast tolerance. Risk‑stratify by RV dysfunction (echo/CT), biomarkers (troponin/BNP), and clinical instability to anticipate decompensation.
Treatment Strategy & Disposition
Anticoagulate promptly when suspicion is high and bleeding risk acceptable; choose DOACs for most stable patients, LMWH in cancer, and UFH if thrombolysis or procedures are possible. Consider systemic thrombolysis or catheter‑directed therapy for massive/submassive PE with deterioration. Assess for precipitating factors and plan duration of therapy (provoked 3 mo; unprovoked often extended). ICU for shock or advanced support; otherwise ward or outpatient pathways for low‑risk cases with reliable follow‑up.
Management Notes
Document shared decision-making. Provide a written anticoagulation plan.
Epidemiology / Risk Factors
- Smoking/chronic lung disease; infections or immobility (VTE)
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CXR | Infection/edema/PTX | Consolidation/effusion/PTX | |
| ABG/VBG | Oxygenation/ventilation | Hypoxemia/hypercapnia | |
| CT chest (indicated) | PE/other | Findings vary |
Outpatient Candidacy (Examples)
| Tool | Low‑Risk Definition |
|---|---|
| sPESI | Score 0 |
| Hestia | All criteria negative |
| No RV strain | Normal echo/biomarkers |
| Reliable support | Adherence and follow‑up assured |
| No contraindications | Bleeding risk acceptable |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Catheter-directed therapy | Localized fibrinolysis/thrombectomy | Rapid | When systemic lysis high risk or ineffective | Bleeding; expertise required; outpatient use |
| Enoxaparin (LMWH) | Xa>IIa inhibition | Hours | Preferred initial AC in many stable cases; cancer VTE | Avoid severe renal failure; outpatient use |
| Apixaban/Rivaroxaban | Direct factor Xa inhibition | Hours | First-line for most stable PE/DVT | Bleeding; interactions; outpatient use |
| Alteplase (systemic) | Plasminogen activation (fibrinolysis) | Rapid | Massive PE with shock or arrest | ICH/major bleed; contraindications; outpatient use |
| Unfractionated heparin (IV) | Antithrombin-mediated Xa/IIa inhibition | Immediate | Initial AC when lysis/cath possible or renal failure | Bleeding, HIT; monitor aPTT; outpatient use |
Prognosis / Complications
- Depends on severity/oxygenation; respiratory failure risk
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
References
- ESC/ACEP PE Outpatient Pathways — Link
Use the Library, QBank, CCS, and analytics in one study workflow.
You just reviewed Pulmonary Embolism — Risk Stratification & Outpatient Management. MDSteps helps you turn that review into exam-style practice, missed-item flashcards, and a readiness dashboard that shows what to study next.
- 16,000+ USMLE-style questions across Step 1, Step 2, and Step 3
- CCS simulator with timed orders, live vitals, and case feedback
- Depth-on-Demand™ explanations and Anki-exportable flashcards
- Library + QBank + analytics for $27/month or $299 lifetime